Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials

BACKGROUND: Pegloticase is approved in the US for treatment of refractory chronic gout. Since chronic kidney disease (CKD) is common in these patients, we conducted a post-hoc analysis of 2 replicate phase 3 trials and the subsequent open-label extension study to determine the effects of pegloticase...

Descripción completa

Detalles Bibliográficos
Autores principales: Yood, Robert A, Ottery, Faith D, Irish, William, Wolfson, Marsha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937145/
https://www.ncbi.nlm.nih.gov/pubmed/24447425
http://dx.doi.org/10.1186/1756-0500-7-54

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937145/
https://www.ncbi.nlm.nih.gov/pubmed/24447425
http://dx.doi.org/10.1186/1756-0500-7-54

Ejemplares similares